サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1378763

多発性硬化症治療薬市場：世界の産業動向、シェア、市場規模、成長、機会、2023-2028年予測

Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 144 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
多発性硬化症治療薬市場：世界の産業動向、シェア、市場規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界の多発性硬化症治療薬の市場規模は、2022年に258億米ドルに達しました。今後、IMARCグループは、2022年から2028年にかけて4.5%の成長率（CAGR）を示し、2028年には336億米ドルに達すると予測しています。

多発性硬化症（MS）は、脊髄や脳の神経細胞の脱髄、軸索切断、神経変性を引き起こす可能性のある、免疫介在性の慢性炎症性疾患を指します。一般的に用いられる治療法には、注射薬、経口薬、点滴薬、筋弛緩薬、抗うつ薬、理学療法などがあります。注射薬にはインターフェロンβやグラチラマー酢酸塩などがあり、皮下や筋肉内に投与されます。内服薬にはフマル酸ジメチル、テリフルノミド、クラドリビンなどがあり、点滴治療にはオクレリズマブ、ナタリズマブ、アレムツズマブなどがあり、これらは静脈内に投与されます。これらの薬は、再発の頻度を最小限に抑え、患者の心拍数と血圧をコントロールするために、症状の管理を助ける。

再発寛解型多発性硬化症（RRMS）、原発性進行性MS（PPMS）、二次性進行性MS（SPMS）、進行性再発性MS（PRMS）の世界の有病率の増加は、市場の成長を促進する重要な要因の1つです。さらに、このような病気にかかりやすい老年人口が増加していることも、市場の成長を後押ししています。ヘルスケアプロバイダーは、自己免疫発作を制御し、MSを患う患者の再発を予防する免疫抑制剤を広く使用しています。さらに、MSの効果的な治療のための革新的なモノクローナル体、免疫調節剤、免疫抑制剤、インターフェロンの開発など、様々な技術的進歩が他の主要な成長促進要因として作用しています。これとは別に、先進国、新興国を問わず、政府は大衆の間で利用可能な治療法に関する認識を高めるためのキャンペーンを展開しており、これがひいては市場に明るい展望をもたらしています。その他の要因としては、広範な研究開発（R&D）活動、ヘルスケアインフラの改善などがあり、市場をさらに牽引すると予想されます。

本レポートで扱う主な質問

  • 世界の多発性硬化症治療薬市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界の多発性硬化症治療薬市場に与えた影響は？
  • 主要な地域市場は？
  • 薬剤別の市場内訳は？
  • 薬剤タイプ別の市場内訳は？
  • 投与経路に基づく市場内訳は？
  • 販売チャネル別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主な促進要因と課題は何か？
  • 世界の多発性硬化症治療薬市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の多発性硬化症治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤別

  • 免疫調節薬
    • 市場動向
    • 主要タイプ
      • コパキソン
      • アボネックス／プレグリディ
      • ジルネア
      • タイサブリ
      • ベタセロン／エクスタビア
      • テシフィデラ
      • レビフ
      • アンピラ
    • 市場予測
  • 免疫抑制剤
    • 市場動向
    • 主な種類
      • オーバージオ
      • レムトラダ
      • オクレリズマブ
      • ジンブライタ
    • 市場予測

第7章 市場内訳：薬剤タイプ別

  • 生物学的製剤
    • 市場動向
    • 市場予測
  • 低分子医薬品
    • 市場動向
    • 市場予測

第8章 市場内訳：投与経路別

  • 経口剤
    • 市場動向
    • 市場予測
  • 注射剤
    • 市場動向
    • 市場予測
  • 静脈注射剤
    • 市場動向
    • 市場予測

第9章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2022
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2022
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2022
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million US$), 2023-2028
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million US$), 2023-2028
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million US$), 2023-2028
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player
目次
Product Code: SR112023A2571

Abstract

The global multiple sclerosis therapies market size reached US$ 25.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4.5% during 2022-2028.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.

Breakup by Drug:

Immunomodulators

Copaxone

Avonex/Plegridy

Gilneya

Tysabri

Betaseron/Extavia

Tecifidera

Rebif

Ampyra

Immunosuppressants

Aubagio

Lemtrada

Ocrelizumab

Zinbryta

Breakup by Drug Type:

Biologic Drugs

Small Molecule Drugs

Breakup by Route of Administration:

Oral

Injectable

Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis